Difference between revisions of "TRK fusions"
Jump to navigation
Jump to search
(→General: ref) |
|||
| Line 2: | Line 2: | ||
==General== | ==General== | ||
Genes:<ref>https://www.ncbi.nlm.nih.gov/pubmed/27843590</ref> | Genes:<ref name=pmid27843590>{{cite journal |vauthors=Amatu A, Sartore-Bianchi A, Siena S |title=NTRK gene fusions as novel targets of cancer therapy across multiple tumour types |journal=ESMO Open |volume=1 |issue=2 |pages=e000023 |date=2016 |pmid=27843590 |pmc=5070277 |doi=10.1136/esmoopen-2015-000023 |url=https://www.ncbi.nlm.nih.gov/pubmed/27843590}}</ref> | ||
*NTRK1. | *NTRK1. | ||
*NTRK2. | *NTRK2. | ||
Revision as of 06:35, 11 September 2018
TRK fusions are seen in many solid tumours of children and adults and have targeted drugs.[1]
General
Genes:[2]
- NTRK1.
- NTRK2.
- NTRK3.
Notes:
- The TRK genes are tropomyosine kinase receptors.
- Multiple fusion partners for each gene.
Testing:
- RNA-based next generation sequencing.
- Immunohistochemistry[3] - limited sensitivity?
Associations
Classic
- Mammary analogue secretory carcinoma (MASC) - ETV6-NTRK3.[4]
- Secretory breast carcinoma - ETV6-NTRK3.[5]
Others
Drugs
- Merestinib.
- Larotrectinib.[1]
- Others.
See also
References
- ↑ 1.0 1.1 Drilon, A.; Laetsch, TW.; Kummar, S.; DuBois, SG.; Lassen, UN.; Demetri, GD.; Nathenson, M.; Doebele, RC. et al. (02 2018). "Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.". N Engl J Med 378 (8): 731-739. doi:10.1056/NEJMoa1714448. PMID 29466156.
- ↑ "NTRK gene fusions as novel targets of cancer therapy across multiple tumour types". ESMO Open 1 (2): e000023. 2016. doi:10.1136/esmoopen-2015-000023. PMC 5070277. PMID 27843590. https://www.ncbi.nlm.nih.gov/pubmed/27843590.
- ↑ Hechtman, JF.; Benayed, R.; Hyman, DM.; Drilon, A.; Zehir, A.; Frosina, D.; Arcila, ME.; Dogan, S. et al. (Nov 2017). "Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.". Am J Surg Pathol 41 (11): 1547-1551. doi:10.1097/PAS.0000000000000911. PMID 28719467.
- ↑ Lei, Y.; Chiosea, SI. (Jun 2012). "Re-evaluating historic cohort of salivary acinic cell carcinoma with new diagnostic tools.". Head Neck Pathol 6 (2): 166-70. doi:10.1007/s12105-011-0312-9. PMID 22127547.
- ↑ Vasudev, P.; Onuma, K. (Dec 2011). "Secretory breast carcinoma: unique, triple-negative carcinoma with a favorable prognosis and characteristic molecular expression.". Arch Pathol Lab Med 135 (12): 1606-10. doi:10.5858/arpa.2010-0351-RS. PMID 22129193.
- ↑ Sheng, WQ.; Hisaoka, M.; Okamoto, S.; Tanaka, A.; Meis-Kindblom, JM.; Kindblom, LG.; Ishida, T.; Nojima, T. et al. (Mar 2001). "Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues.". Am J Clin Pathol 115 (3): 348-55. doi:10.1309/3H24-E7T7-V37G-AKKQ. PMID 11242790.
- ↑ Halalsheh, H.; McCarville, MB.; Neel, M.; Reynolds, M.; Cox, MC.; Pappo, AS. (Oct 2018). "Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma.". Pediatr Blood Cancer 65 (10): e27271. doi:10.1002/pbc.27271. PMID 29893456.
- ↑ Rudzinski, ER.; Lockwood, CM.; Stohr, BA.; Vargas, SO.; Sheridan, R.; Black, JO.; Rajaram, V.; Laetsch, TW. et al. (Jul 2018). "Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.". Am J Surg Pathol 42 (7): 927-935. doi:10.1097/PAS.0000000000001062. PMID 29683818.